Latest news with #Epigral
Time of India
3 days ago
- Business
- Time of India
Epigral to expand wind-solar hybrid power plant to 38.14 MW, Manufacturing News, ET Manufacturing
Advt Specialty chemical manufacturer Epigral said on Wednesday it will more than double its wind-solar hybrid power capacity to 38.14 megawatt (MW) from 18.34 MW through a Rs 21.38-crore company will invest Rs 21.38 crore for a 26 per cent stake in a special purpose vehicle (SPV) created in partnership with Prozeal Green Energy Ltd to add 19.80 MW renewable strategic partnership will be formalised for 25 years through an energy subscription agreement and share subscription and shareholder agreement between the two companies, Epigral said in a capacity expansion is expected to be commissioned by the fourth quarter of FY26 and will help meet rising power demands from upcoming projects, the company said."The capacity expansion will be important to meet our rising energy demands," Epigral Chairman and Managing Director Maulik Patel has announced plans to expand capacity for CPVC Resin to 150,000 tonnes per annum and Epichlorohydrin (ECH) to 100,000 tonnes per annum. The company recently commissioned a chlorotoluene value chain plant at its Dahej facility in renewable energy expansion reflects the company's strategy to secure clean power while pursuing aggressive growth in the specialty chemicals sector
Time of India
3 days ago
- Business
- Time of India
Epigral to expand wind-solar hybrid power plant to 38.14 MW
Specialty chemical manufacturer Epigral said on Wednesday it will more than double its wind-solar hybrid power capacity to 38.14 megawatt (MW) from 18.34 MW through a Rs 21.38-crore investment. The company will invest Rs 21.38 crore for a 26 per cent stake in a special purpose vehicle (SPV) created in partnership with Prozeal Green Energy Ltd to add 19.80 MW renewable capacity. The strategic partnership will be formalised for 25 years through an energy subscription agreement and share subscription and shareholder agreement between the two companies, Epigral said in a statement. The capacity expansion is expected to be commissioned by the fourth quarter of FY26 and will help meet rising power demands from upcoming projects, the company said. "The capacity expansion will be important to meet our rising energy demands," Epigral Chairman and Managing Director Maulik Patel said. Live Events Epigral has announced plans to expand capacity for CPVC Resin to 150,000 tonnes per annum and Epichlorohydrin (ECH) to 100,000 tonnes per annum. The company recently commissioned a chlorotoluene value chain plant at its Dahej facility in Gujarat. The renewable energy expansion reflects the company's strategy to secure clean power while pursuing aggressive growth in the specialty chemicals sector .
Business Standard
6 days ago
- Business
- Business Standard
Epigral signs agreement to source 19.80 MW wind solar hybrid power
Epigral as on today 04 June 2025 has executed (I) Share Subscription and Shareholder's Agreement with Prozeal Green Power (Promoter) and Pro-Zeal Green Power Ten (Power Producer) and (II) Energy Supply Agreement with 'Pro-Zeal Green Power Ten to source a contracted capacity of 19.80 MW 'Wind Solar Hybrid (WSH) Power' (Project) as a Captive Consumer from WSH power plant located in the State of Gujarat. This transaction entails subscription of minimum 26% of Securities (Equity and Optionally Convertible Debentures, in one or more tranches) of Power Producer, a Special Purpose Vehicle (SPV) formed for developing, constructing, operating and maintaining the said Project. Sourcing power from renewable resources is in line with the Company's commitment towards sustainability goals.
Business Upturn
7 days ago
- Business
- Business Upturn
Epigral acquires 26% stake in renewable energy SPV for Rs 21.38 crore
By Aman Shukla Published on June 4, 2025, 11:13 IST Epigral Limited has announced the execution of agreements to invest in a renewable energy project in Gujarat. On June 4, 2025, the company entered into a Share Subscription and Shareholder's Agreement with Prozeal Green Power Private Limited and Pro-Zeal Green Power Ten Private Limited. Additionally, it signed an Energy Supply Agreement with Pro-Zeal Green Power Ten Private Limited to source 19.80 MW of Wind Solar Hybrid (WSH) power as a captive consumer. As part of this transaction, Epigral will subscribe to at least 26% of the securities—comprising equity and optionally convertible debentures—of Pro-Zeal Green Power Ten Private Limited, a special purpose vehicle (SPV) formed to develop and operate the WSH power project. The investment will be made in one or more tranches, totaling approximately ₹21.38 crore, and will be through cash consideration. The SPV was incorporated on January 2, 2025, and is yet to begin commercial operations. Its current paid-up capital is ₹1 lakh. Following the transaction, Pro-Zeal Green Power Ten will become an associate of Epigral. The ownership in the SPV will be held in the ratio of 26:74 by Epigral and Prozeal Green Power Private Limited, respectively. This strategic move aligns with Epigral's efforts to secure power for its future expansion projects while progressing towards its sustainability goals. The transaction has been carried out at arm's length and does not require any regulatory approvals. Aman Shukla is a post-graduate in mass communication . A media enthusiast who has a strong hold on communication ,content writing and copy writing. Aman is currently working as journalist at
Entrepreneur
06-05-2025
- Business
- Entrepreneur
Epigral Posts 13% YoY Rise in PAT for Q4FY25 Reaching INR 87 Crore
Epigral also announced major expansion plans to support future growth. Capacity for CPVC Resin and Epichlorohydrin is set to double, with new facilities expected to be operational in the first half of FY2027 You're reading Entrepreneur India, an international franchise of Entrepreneur Media. Epigral, an integrated chemical manufacturer, reported a robust set of financial results for the quarter and full year ended March 31, 2025, according to its latest regulatory filing. The company posted a 13 per cent year-on-year (YoY) rise in profit after tax (PAT) for Q4FY25, reaching INR 87 crore, compared to INR 77 crore in the same quarter last year. Revenue for the quarter surged 20 per cent to INR 631 crore, driven largely by volume growth in the high-margin derivatives & specialty segment. The company's financial health showed marked improvement, with return on capital employed (ROCE) climbing to 25 per cent in FY2025, up from 18 per cent a year ago. Its net debt to EBITDA ratio more than halved to 0.7x from 2.0x, while CRISIL upgraded Epigral's credit rating to AA, up from AA-, reflecting enhanced fiscal stability and operational performance. Chairman and managing director, Maulik Patel, emphasized the significance of the company's trajectory, stating, "We ended FY2025 with the highest ever revenue of INR 2,565 crore, a growth of 33 per cent compared to the previous year. This growth is on account of volume rise of 11 per cent, majorly from high value products." Notably, the derivatives & specialty segment played a pivotal role in this performance, growing by 24 per cent in volume terms and increasing its revenue contribution to 54 per cent from 45 per cent in FY2024. The company also raised INR 333 crore through a qualified institutional placement (QIP), which was used to fund its ongoing capital expenditure of INR 195 crore during FY2025. Looking ahead, Patel noted, "We are geared up and strengthened our position to grow further, by focusing on import substitute products, further diversifying and increasing derivatives & specialty business and with prudence allocation of capital, rewarding our stakeholders." The board has proposed a final dividend of INR 3.5 per share, bringing the total dividend for FY2025 to INR six per share.
